Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

Castration Resistant ◽

Circulating Tumour Cell ◽

Cell Enumeration ◽

Development And Validation

Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2019.08.005 ◽

2019 ◽

Vol 121 ◽

pp. 48-54 ◽

Cited By ~ 3

Author(s):

Bodine P.S. Belderbos ◽

Anieta M. Sieuwerts ◽

Esther Oomen-de Hoop ◽

Bianca Mostert ◽

Jaco Kraan ◽

...

Keyword(s):

Prostate Cancer ◽

Cell Count ◽

Tumour Cell ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Castration Resistant ◽

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2019.04.006 ◽

2019 ◽

Vol 76 (5) ◽

pp. 676-685 ◽

Cited By ~ 22

Author(s):

Adam Sharp ◽

Jon C. Welti ◽

Maryou B.K. Lambros ◽

David Dolling ◽

Daniel Nava Rodrigues ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Tumour Cell ◽

Splice Variant ◽

Clinical Utility ◽

Castration Resistant ◽

Circulating Tumour Cell ◽

Androgen Receptor Splice Variant

Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e16034 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16034-e16034

Author(s):

Luis Leon Mateos ◽

Laura Muinelo ◽

Begoña Perez-Valderrama ◽

Begoña Mellado ◽

María José Juan Fita ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Tumour Cell ◽

Phase Ii Study ◽

Castration Resistant ◽

Docetaxel Treatment ◽

CTC-STOP Trial: A trial to determine if the use of Circulating Tumour Cell (CTC) counts can direct early discontinuation of docetaxel chemotherapy in patients with metastatic castration resistant prostate cancer (mCRPC), when compared with standard approaches to guide treatment switch decisions

http://isrctn.com/ ◽

10.1186/isrctn82499869 ◽

2017 ◽

Author(s):

Marie Hyslop

Keyword(s):

Prostate Cancer ◽

Tumour Cell ◽

Early Discontinuation ◽

Castration Resistant ◽

Stop Trial ◽

Circulating Tumour Cell ◽

Treatment Switch ◽

Docetaxel Chemotherapy

Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)

Annals of Oncology ◽

10.1093/annonc/mdw372.37 ◽

2016 ◽

Vol 27 ◽

pp. vi255 ◽

Cited By ~ 1

Author(s):

U. Anido ◽

M.J. Juan Fita ◽

L. Munielo-Romay ◽

B. Pérez-Valderrama ◽

B. Mellado ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Tumour Cell ◽

Phase Ii Study ◽

Castration Resistant ◽

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Annals of Oncology ◽

10.1093/annonc/mdn544 ◽

2009 ◽

Vol 20 (1) ◽

pp. 27-33 ◽

Cited By ~ 171

Author(s):

D. Olmos ◽

H.-T. Arkenau ◽

J.E. Ang ◽

I. Ledaki ◽

G. Attard ◽

...

Keyword(s):

Prostate Cancer ◽

Tumour Cell ◽

Single Centre ◽

End Points ◽

Castration Resistant ◽

Single Centre Experience ◽

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts

Annals of Oncology ◽

10.1093/annonc/mdy172 ◽

2018 ◽

Vol 29 (7) ◽

pp. 1554-1560 ◽

Cited By ~ 28

Author(s):

D. Lorente ◽

D. Olmos ◽

J. Mateo ◽

D. Dolling ◽

D. Bianchini ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Progression ◽

Cancer Patients ◽

Tumour Cell ◽

Castration Resistant ◽

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

ESMO Open ◽

10.1016/j.esmoop.2021.100241 ◽

2021 ◽

Vol 6 (5) ◽

pp. 100241

Author(s):

R. de Wit ◽

C. Wülfing ◽

D. Castellano ◽

G. Kramer ◽

J.-C. Eymard ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Biomarker ◽

Neutrophil To Lymphocyte Ratio ◽

Predictive And Prognostic Biomarker

Lymphocyte Ratio ◽

Castration Resistant ◽

Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2017.12.004 ◽

2018 ◽

Vol 73 (4) ◽

pp. 639-640 ◽

Cited By ~ 1

Author(s):

Bernardo Rocco ◽

Ahmed Eissa ◽

Giampaolo Bianchi

Keyword(s):

Prostate Cancer ◽

Computed Tomography ◽

Positron Emission Tomography ◽

Prognostic Biomarker ◽

Receptor Expression ◽

Emission Tomography ◽

Castration Resistant ◽

Positron Emission ◽

Glycolytic Activity

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer

Oncotarget ◽

10.18632/oncotarget.6167 ◽

2015 ◽

Vol 6 (39) ◽

pp. 41825-41836 ◽

Cited By ~ 22

Author(s):

Kun Chang ◽

Yun-Yi Kong ◽

Bo Dai ◽

Ding-Wei Ye ◽

Yuan-Yuan Qu ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cell ◽

Tumor Marker ◽

Treatment Effect ◽

Circulating Tumor Cell ◽

Castration Resistant ◽

Cell Enumeration ◽

Marker Detection